
WHAT IS CLAIMED IS:


1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:


the moiety of "-N(R^1)(R^2)" is a moiety of Formula a-13



a-13,

wherein t1 is 0, 1, 2, or 3;

or the moiety of "-N(R^1)(R^2)" is a moiety of Formula a-26



a-26,

wherein ring A^2 is 5- or 6- membered cycloalkyl or heterocycloalkyl;

t2 is 0, 1, 2, or 3; and

t3 is 0, 1, 2, or 3.;

each of R^5 and R^6 is H;

R^7 is H or -P(=O)(OR^{81})(OR^{82});

R^8 is $–L^1$-R^{11}, $–L^2$-R^{12}, $–L^3$-R^{13}, $–L^4$-R^{14}, -C(R^{15})(Cy^1)(Cy^2), -C(R^{15})(Cy^1)[-NR^{23}-$S(=O)_2$-Cy^2], or $–L^5$-N(-L^6-Cy^3)(-L^7-Cy^4);

each R^9 is independently OH, oxo, halogen, optionally substituted C_{1-4} alkyl, optionally substituted C_{1-4} alkoxy, or optionally substituted C_{3-6} cycloalkyl;

each of L^1, L^2, L^3, and L^4 is independently absent, -($CR^{21}R^{22}$)$_m$-, -NR^{23}-, -O-, -C(=O)-, -$S(=O)_2$-, -$S(=O)_2$-($CR^{21}R^{22}$)$_n$-, -C(=O)-($CR^{21}R^{22}$)$_n$-, -$S(=O)_2$-NR^{23}-, -C(=O)-NR^{23}-, -($CR^{21}R^{22}$)$_{f1}$-NR^{23}-($CR^{21}R^{22}$)$_{f2}$-, -($CR^{21}R^{22}$)$_{f1}$-O-($CR^{21}R^{22}$)$_{f2}$-, -C(=O)-NR^{23}-($CR^{21}R^{22}$)$_p$-, or -$S(=O)_2$-NR^{23}-($CR^{21}R^{22}$)$_p$-;

L^5 is absent or -($CR^{21}R^{22}$)-;

L^6 is absent or -($CR^{21}R^{22}$)-;

L^7 is absent, -($CR^{21}R^{22}$)-, or -$S(=O)_2$-;

R^{11} is 5- to 10-membered heteroaryl optionally substituted with one or more independently selected R^{31};

R^{12} is 4- to 14-membered heterocycloalkyl optionally substituted with one or more independently selected R^{32};

R^{13} is C_{6-10} aryl optionally substituted with one or more independently selected R^{33};

R^{14} is C_{3-14} cycloalkyl optionally substituted with one or more independently selected R^{34};

R^{15} is H, OH, halogen, C_{1-4} alkoxy, C_{1-4} alkyl, or cyclopropyl;

each of R^{21} and R^{22} is independently H, OH, halogen, C_{1-3} alkyl, or cyclopropyl, wherein the C_{1-3} alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of OH, halogen, C_{1-3} alkoxy, C_{1-3} haloalkoxy, and cyclopropyl;

R^{23} is H, C_{1-4} alkyl, or cyclopropyl;

each of R^{31}, R^{32}, R^{33}, and R^{34} is independently selected from the group consisting of halogen, -N(R^a)(R^b), -N(R^c)(C(=O)R^d), -N(R^c)($S(=O)_2R^d$), -C(=O)-N(R^a)(R^b), -C(=O)-R^d, -C(=O)-OR^d, -OC(=O)-R^d, -N(R^c)($S(=O)_2R^d$), -$S(=O)_2$-N(R^a)(R^b), -SR^d, -$S(=O)_2R^d$, –OR^d, -OR^{35}, -CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, (C_{3-10} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl-, wherein each of the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, (C_{3-10} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl- is optionally

substituted with one or more independently selected R^{36}; and wherein each of the C_{1-6} alkyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, (C_{3-10} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl- is further optionally substituted one or more oxo;

each R^{35} is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, (C_{3-10} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl-, wherein each of the C_{1-6} alkyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, (C_{3-10} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl- is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -CN, -C(=O)C_{1-4} alkyl, -C(=O)OH, -C(=O)O-C_{1-4} alkyl, -C(=O)NHC_{1-4} alkyl, -C(=O)N(C_{1-4} alkyl)$_2$, oxo, -OH, -OC(=O)-C_{1-4} alkyl, -OC(=O)O-C_{1-4} alkyl, -NH_2, -NH(C_{1-4} alkyl), -N(C_{1-4} alkyl)$_2$, -NHC(=O)C_{1-4} alkyl, -NHC(=O)OC_{1-4} alkyl, -NHC(=O)NHC_{1-4} alkyl, and C_{1-4} alkoxy;

each R^{36} is independently selected from the group consisting of halogen, -OH, -NO_2, -CN, -SF_5, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, -N(R^a)(R^b), -N(R^c)(C(=O)R^d), -C(=O)-N(R^a)(R^b), -C(=O)-R^d, -C(=O)-OR^d, -OC(=O)-R^d, -N(R^c)($S(=O)_2R^d$), -$S(=O)_2$-N(R^a)(R^b), -SR^d, -$S(=O)_2R^d$, and –OR^d, wherein each of the C_{1-6} alkyl, C_{3-7} cycloalkyl, and heterocycloalkyl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl, -N(R^a)(R^b), -N(R^c)(C(=O)R^d), -C(=O)-OR^d, -C(=O)H, -C(=O)R^d, -C(=O)N(R^a)(R^b), -N(R^c)($S(=O)_2R^d$), -$S(=O)_2$-N(R^a)(R^b), -SR^d, -$S(=O)_2R^d$, and –OR^d;

each of R^{81} and R^{82} is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-7} cycloalkyl, and (C_{3-7} cycloalkyl)-C_{1-4} alkyl-, wherein each of the C_{1-6} alkyl, C_{3-7} cycloalkyl, and (C_{3-7} cycloalkyl)-C_{1-4} alkyl- is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OH, oxo, -NH_2, -NH(C_{1-4} alkyl), -N(C_{1-4} alkyl)$_2$, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl;

or OR^{81} and OR^{82}, together with the P(=O) to which they are attached, form 4- to 10-membered heterocycloalkyl that is further optionally substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OH, oxo, -NH_2, -NH(C_{1-4} alkyl), -N(C_{1-4} alkyl)$_2$, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, and C_{3-6} cycloalkyl;

each of Cy^1, Cy^2, Cy^3, and Cy^4 is independently selected from the group consisting of R^{11}, R^{12}, R^{13}, and R^{14};

each R^a is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-7} cycloalkyl, or (C_{3-7} cycloalkyl)-C_{1-4} alkyl-;

each R^b is independently H or selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl-, wherein each of the selections from the group is optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} hydroxylalkyl, -S-C_{1-4} alkyl, -C(=O)H, -C(=O)-C_{1-4} alkyl, -C(=O)-O-C_{1-4} alkyl, -C(=O)-NH_2, -C(=O)-N(C_{1-4} alkyl)$_2$, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

or R^a and R^b, together with the N atom to which they are attached, form a 4- to 10-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, each optionally substituted with one or more substituents each independently selected from the group consisting of halogen, -OH, oxo, -C(=O)H, -C(=O)OH, -C(=O)-C_{1-4} alkyl, -C(=O)-NH_2, -C(=O)-N(C_{1-4} alkyl)$_2$, -CN, C_{1-4} alkyl, C_{3-6} cycloalkyl, (C_{3-6} cycloalkyl)-C_{1-2} alkyl-, C_{1-4} alkoxy, C_{1-4} hydroxylalkyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

each R^c is independently selected from the group consisting of H, C_{1-4} alkyl, C_{3-7} cycloalkyl, and (C_{3-7} cycloalkyl)-C_{1-4} alkyl-;

each R^d is independently selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)-C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)-C_{1-4} alkyl-, (C_{6-10} aryl)-C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)-C_{1-4} alkyl-, wherein each of the selections from the group is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, -CF_3, -CN, -OH, oxo, -S-C_{1-4} alkyl, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;


each of f1 and f2 is independently 0, 1, or 2, provided that the sum of f1 and f2 is 1, 2, or 3;

m is 1, 2, or 3;

n is 1, 2, or 3; and

p is 1, or 2.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I or pharmaceutically acceptable salt thereof is a compound of I-a1 :




I-a1


or pharmaceutically acceptable salt thereof.

3. The compound of Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein:


the moiety of "–N(R^1)(R^2)" is a moiety of Formula a-46-1, a-46-2, a-46-3, a-46-4, a-46-5, a-46-6, or a-46-7:




a-46-1




a-46-2




a-46-3




a-46-4



a-46-5



a-46-6



a-46-7

t2 is 0, 1, 2, or 3;

t3 is 0, 1, or 2;

t4 is 0, 1, or 2; and

each R^{9b} is independently F, Cl, methyl, or C_1 fluoroalkyl.

4. The compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein the moiety of "$–N(R^1)(R^2)$" is a moiety of Formula a-46-1; R^8 is $–L^1\text{-}R^{11}$ or $–L^3\text{-}R^{13}$; and each of L^1 and L^3 is -C(=O)- or $\text{-S(=O)}_2\text{-}$.

5. The compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein the moiety of "$–N(R^1)(R^2)$" is a moiety of Formula a-46-2.

6. The compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein R^8 is $\text{-O-}R^{11}$ or $\text{-O-}R^{13}$.

7. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the moiety of "$–N(R^1)(R^2)$" is a moiety of Formula a-13 and R^8 is $–L^1\text{-}R^{11}$ or $–L^3\text{-}R^{13}$.

8. The compound of Claim 7, or a pharmaceutically acceptable salt thereof, wherein R^8 is $\text{-}R^{11}$ or $\text{-}R^{13}$.

9. The compound of Claim 8, or a pharmaceutically acceptable salt thereof, wherein R^8 is $\text{-}R^{11}$.

10. A compound of claim 1 selected from:

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*S*)-3-[(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-[(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(3-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(4-fluorophenyl)sulfonyl]-3-hydroxy-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-3,3,3-trifluoro-2-[({(3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]dec-8-yl}carbonyl)oxy]propyl dihydrogen phosphate;

(2*R*)-3,3,3-trifluoro-2-[({4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl dihydrogen phosphate;

(2*R*)-3,3,3-trifluoro-2-[({4-[(3-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl dihydrogen phosphate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-(4-fluorobenzyl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(3,4-difluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(4-ethynylphenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-(4-fluorobenzyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate;

(2*R*)-3,3,3-trifluoro-2-({[4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undec-9-yl]carbonyl}oxy)propyl dihydrogen phosphate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate, DIAST-1;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate, DIAST-2;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-[(cyclopropylsulfonyl)(methyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-[benzoyl(methyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-{[(cyclopropylmethyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-[3-(trifluoromethoxy)phenyl]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 2-(cyclopentylcarbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-{methyl[(2,2,2-trifluoroethyl)sulfonyl]amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-{methyl[(2-methylpropyl)sulfonyl]amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;

(2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-[(cyclopropylacetyl)(methyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate; and

(2*R*)-3,3,3-trifluoro-2-({[(3*R*)-3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]dec-8-yl]carbonyl}oxy)propyl dihydrogen phosphate,

or a pharmaceutically acceptable salt thereof.

11. A compound of claim 1 selected from:

(2*R*)-3,3,3-trifluoro-2-[({(3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]dec-8-yl}carbonyl)oxy]propyl phosphate, disodium salt;

(2*R*)-3,3,3-trifluoro-2-[({4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl phosphate, disodium salt;

(2*R*)-3,3,3-trifluoro-2-[({4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl phosphate, (bis)-L-lysine salt;

(2*R*)-3,3,3-trifluoro-2-[({4-[(3-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl phosphate, disodium salt;

(2*R*)-3,3,3-trifluoro-2-({[4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undec-9-yl]carbonyl}oxy)propyl phosphate, disodium salt;

(2*R*)-3,3,3-trifluoro-2-[({(3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]dec-8-yl}carbonyl)oxy]propyl phosphate, (bis)-L-lysine salt;

(2*R*)-3,3,3-trifluoro-2-({[4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undec-9-yl]carbonyl}oxy)propyl phosphate, (bis)-L-lysine salt, and

(2*R*)-3,3,3-trifluoro-2-({[(3*R*)-3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]dec-8-yl]carbonyl}oxy)propyl phosphate, (bis)-L-lysine salt.

12. A compound of Claim 1 that is (2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate, or a pharmaceutically acceptable salt thereof.

13. A compound of Claim 1 that is (2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate, or a pharmaceutically acceptable salt thereof.

14. A compound of Claim 1 that is (2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl (3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate, or a pharmaceutically acceptable salt thereof.

15. A compound of Claim 1 that is (2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate, DIAST-1; or (2*R*)-1,1,1-trifluoro-3-hydroxypropan-2-yl 3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]decane-8-carboxylate, DIAST-2; or a pharmaceutically acceptable salt thereof.

16. A compound of Claim 1 that is (2*R*)-3,3,3-trifluoro-2-[({(3*R*)-3-[methyl(phenylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]dec-8-yl}carbonyl)oxy]propyl dihydrogen phosphate, or a pharmaceutically acceptable salt thereof.

17. A compound of Claim 1 that is (2*R*)-3,3,3-trifluoro-2-[({4-[(4-fluorophenyl)sulfonyl]-1-oxa-4,9-diazaspiro[5.5]undec-9-yl}carbonyl)oxy]propyl dihydrogen phosphate, or a pharmaceutically acceptable salt thereof.

18. A compound of Claim 1 that is (2*R*)-3,3,3-trifluoro-2-({[(3*R*)-3-{[(4-fluorophenyl)sulfonyl](methyl)amino}-1-oxa-8-azaspiro[4.5]dec-8-yl]carbonyl}oxy)propyl dihydrogen phosphate, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt according to any one of Claims 1 to 18, and a pharmaceutically acceptable carrier.

20. A compound or pharmaceutically acceptable salt according to any one of Claims 1 to 18 for use in the treatment of a disorder selected from the group consisting of a metabolic disorder; a kidney disease; vomiting or emesis; nausea; an eating disorder; neuropathy; burning feet syndrome; a neurodegenerative disorder; a cardiovascular disease; osteoporosis; osteoarthritis; schizophrenia; depression; bipolar disease; tremor; dyskinesia; dystonia; spasticity; Tourette’s syndrome; sleep apnea; hearing loss; an eye disease; cachexia; insomnia; meningitis; sleeping sickness; progressive multifocal leukoencephalopathy; De Vivo disease; cerebral edema; cerebral palsy; withdrawal syndrome; traumatic brain injury; non-traumatic brain injury; spinal cord injury; seizures; excitotoxin exposure; ischemia; liver fibrosis, iron overload, cirrhosis of the liver; a lung disorder; a liver disorder, stroke; subarachnoid hemorrhage; intracerebral hemorrhage; vasospasm; AIDS wasting syndrome; renal ischemia; a disorder associated with abnormal cell growth or proliferation; an autoimmune disease; an inflammatory disorder; a disorder of the immune system; post-traumatic stress disorder (PTSD); acute stress

disorder; panic disorder; substance-induced anxiety; obsessive-compulsive disorder (OCD); agoraphobia; specific phobia; social phobia; anxiety disorder; attention deficit disorder (ADD); attention deficit hyperactivity disorder (ADHD); Asperger's syndrome; pain; a demyelinating disease; and cognitive impairment.